Roex, Marthe C. J.
van Balen, Peter
Germeroth, Lothar
Hageman, Lois
van Egmond, Esther
Veld, Sabrina A. J.
Hoogstraten, Conny
van Liempt, Ellis
Zwaginga, Jaap J.
de Wreede, Liesbeth C.
Meij, Pauline
Vossen, Ann C. T. M.
Danhof, Sophia http://orcid.org/0000-0003-1316-0241
Einsele, Hermann
Schaafsma, M. Ron
Veelken, Hendrik
Halkes, Constantijn J. M.
Jedema, Inge
Falkenburg, J. H. Frederik
Funding for this research was provided by:
EC | EC Seventh Framework Programm | FP7 Health (601722, 601722, 601722, 601722, 601722, 601722, 601722, 601722, 601722)
KWF Kankerbestrijding (UL 2008-4263, UL 2008-4263)
EC | EC Seventh Framework Programm | FP7 Health
EC | EC Seventh Framework Programm | FP7 Health
EC | EC Seventh Framework Programm | FP7 Health
EC | EC Seventh Framework Programm | FP7 Health
EC | EC Seventh Framework Programm | FP7 Health
EC | EC Seventh Framework Programm | FP7 Health
EC | EC Seventh Framework Programm | FP7 Health
EC | EC Seventh Framework Programm | FP7 Health
Article History
Received: 21 March 2019
Revised: 21 August 2019
Accepted: 27 August 2019
First Online: 17 October 2019
Compliance with ethical standards
:
: LG is senior vice president and managing director of Juno Therapeutics GmbH, a Celgene company (Munich, Germany). The remaining authors declare that they have no conflict of interest.